Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Mindbio Therapeutics Corp. ( (TSE:MBIO) ) is now available.
MindBio Therapeutics Corp. has announced progress on its Phase 2B clinical trials, involving the use of their proprietary psychedelic medicine, MB22001, in treating Major Depressive Disorder and end of life distress in advanced stage cancer patients. These trials, unique in being government-approved for take-home use, are advancing well, with previous phases showing promising results, including sustained anti-depressant responses and improved sleep and wellbeing. The trials highlight MindBio’s innovative approach in making psychedelics accessible for community-based treatment, demonstrating effective implementation of its treatment strategy.
More about Mindbio Therapeutics Corp.
MindBio Therapeutics Corp. is a clinical stage biopharmaceutical company focused on psychiatric medicine development using microdoses of psychedelic medicines to treat depressive disorders.
YTD Price Performance: -25.00%
Average Trading Volume: 109,818
Technical Sentiment Consensus Rating: Buy
Find detailed analytics on MBIO stock on TipRanks’ Stock Analysis page.